Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
What 9 Analyst Ratings Have To Say About Karuna Therapeutics
September 28, 2023
Via
Benzinga
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
September 28, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Analyst Expectations for Karuna Therapeutics's Future
September 08, 2023
Via
Benzinga
Karuna Therapeutics to Present at Upcoming Investor Conferences
August 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
10 Analysts Have This to Say About Karuna Therapeutics
August 22, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
August 04, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
July 13, 2023
Via
Benzinga
Where Karuna Therapeutics Stands With Analysts
June 01, 2023
Via
Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
May 16, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
August 22, 2023
Via
Benzinga
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Leadership Appointments
August 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics's Return On Capital Employed Overview
May 12, 2023
Via
Benzinga
3 Biotech Buyout Targets to Watch
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023
July 20, 2023
Via
Benzinga
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
July 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Why Shares of Karuna Therapeutics Were Up Wednesday
March 22, 2023
The clinical-stage biotech announced positive trial results for its lead therapy.
Via
The Motley Fool
What Are Latest Investor Thoughts On Karuna Therapeutics? Analyst Sees Buying Opportunity
July 14, 2023
William Blair notes increasing investor inbounds on Karuna Therapeutics Inc (NASDAQ: KRTX) given the recent pullback, as the stock is down 13% off June 2023 highs and 25% off 52-week highs
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 06, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 29, 2023
Via
Benzinga
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 30, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
May 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
May 04, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
April 28, 2023
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) released its results for the year ended December 31, 2022, revealing revenue of $15.6 million, a decrease of 10.2% compared to $17.4 million in 2021....
Via
Benzinga
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
April 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
March 24, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
March 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 22, 2023
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.